Literature DB >> 30538294

Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation.

James Ahodantin1,2,3, Myriam Bou-Nader4,5,6, Corinne Cordier7,8, Jérôme Mégret7,8, Patrick Soussan1,2,3, Chantal Desdouets4,5,6, Dina Kremsdorf9,10,11.   

Abstract

Hepatitis B virus X protein (HBx) contributes to Hepatitis B virus (HBV)-related liver cancer. However, its impact on hepatocyte proliferation and genomic stability remains elusive. We studied the role of HBx expression on the progression of cell cycle and liver polyploidization during proliferation and liver carcinogenesis. Full-length HBx transgenic mice (FL-HBx) were developed to investigate liver ploidy as well as hepatocyte proliferation, along normal liver maturation and during cancer initiation (chemical carcinogen treatment). Investigation of postnatal liver development in FL-HBx showed an aberrant G1/S and G2/M transitions, triggered (1) a delay of the formation of hepatocytes binucleation, (2) the early synthesis of polyploidy nuclei (≥4n) and (3) DNA damage appearance. Moreover, HBV infection during hepatocytes proliferation in a humanized liver mouse model led, to modifications in polyploidy of hepatocytes. In initiation of hepatocellular carcinoma, FL-HBx protein decreased ChK1 phosphorylation, Mre11 and Rad51 expression, upregulated IL-6 expression and impaired apoptosis. This was related to DNA damage accumulation in FL-HBx mice. At day 75 after initiation of hepatocellular carcinoma, FL-HBx mice revealed significant cell cycle changes related to the increased amount of 4n nuclei and of markers of cancer progenitor cells. Finally, PLK1 upregulation and p38/ERK activation in FL-HBx mice were implicated in aberrant polyploidization favoring DNA damage propagation and hepatocyte transformation. In conclusion, our data indicate that FL-HBx protein increases DNA damage through the hijack of hepatocyte polyploidization. That leads to enhancement of hepatocellular carcinoma initiation in an inflammatory context.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30538294     DOI: 10.1038/s41388-018-0607-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Liver cell polyploidization: a pivotal role for binuclear hepatocytes.

Authors:  Jacques-Emmanuel Guidotti; Olivier Brégerie; Aude Robert; Pascale Debey; Christian Brechot; Chantal Desdouets
Journal:  J Biol Chem       Date:  2003-03-07       Impact factor: 5.157

2.  Liver tetraploidization is controlled by a new process of incomplete cytokinesis.

Authors:  Germain Margall-Ducos; Séverine Celton-Morizur; Dominique Couton; Olivier Brégerie; Chantal Desdouets
Journal:  J Cell Sci       Date:  2007-09-25       Impact factor: 5.285

3.  Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression.

Authors:  L Qiao; K Leach; R McKinstry; D Gilfor; A Yacoub; J S Park; S Grant; P B Hylemon; P B Fisher; P Dent
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

4.  Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH.

Authors:  Ishtiaq Qadri; Kaneez Fatima; Hany AbdeL-Hafiz
Journal:  BMC Microbiol       Date:  2011-03-04       Impact factor: 3.605

5.  Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes.

Authors:  Chi Tarn; Lin Zou; Ronald L Hullinger; Ourania M Andrisani
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Human hepatocyte polyploidization kinetics in the course of life cycle.

Authors:  B N Kudryavtsev; M V Kudryavtseva; G A Sakuta; G I Stein
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1993

7.  Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.

Authors:  Zi-Li He; He Zheng; Hui Lin; Xiong-Ying Miao; De-Wu Zhong
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

8.  Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice.

Authors:  Nicolas Brezillon; Marie-Noëlle Brunelle; Hélène Massinet; Eric Giang; Céline Lamant; Lucie DaSilva; Sophie Berissi; Jacques Belghiti; Laurent Hannoun; Gherard Puerstinger; Eva Wimmer; Johan Neyts; Olivier Hantz; Patrick Soussan; Serban Morosan; Dina Kremsdorf
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

9.  Liver polyploidy: Dr Jekyll or Mr Hide?

Authors:  Géraldine Gentric; Chantal Desdouets
Journal:  Oncotarget       Date:  2015-04-20

10.  p38α regulates actin cytoskeleton and cytokinesis in hepatocytes during development and aging.

Authors:  Ana M Tormos; Sergio Rius-Pérez; María Jorques; Patricia Rada; Lorena Ramirez; Ángela M Valverde; Ángel R Nebreda; Juan Sastre; Raquel Taléns-Visconti
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

View more
  12 in total

1.  Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.

Authors:  Xian Lin; Ai-Min Li; Yong-Hao Li; Rong-Cheng Luo; Zhen Liu; Yu-Jiao Zou; Yi-Yi Liu; Chen Liu; Ying-Ying Xie; Shi Zuo; Zhan Liu; Wei-Yi Fang
Journal:  Signal Transduct Target Ther       Date:  2020-02-14

Review 2.  Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review.

Authors:  Enakshi Sivasudhan; Neil Blake; Zhiliang Lu; Jia Meng; Rong Rong
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

Review 3.  Polyploidy in liver development, homeostasis and disease.

Authors:  Romain Donne; Maëva Saroul-Aïnama; Pierre Cordier; Séverine Celton-Morizur; Chantal Desdouets
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-02       Impact factor: 46.802

Review 4.  Mouse Models for Immunotherapy in Hepatocellular Carcinoma.

Authors:  Enya Li; Li Lin; Chia-Wei Chen; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

5.  MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma.

Authors:  Xianhai Mao; Bingzhang Tian; Xiaohui Duan; Wei Li; Peng Hu; Bo Jiang; Jianhui Yang; Lixue Zhou
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

6.  Effects of Aurora kinase A on mouse decidualization via Stat3-plk1-cdk1 pathway.

Authors:  Peng-Chao Wang; Si-Ting Chen; Zeng-Ming Yang
Journal:  Reprod Biol Endocrinol       Date:  2021-10-29       Impact factor: 5.211

7.  Long noncoding RNA RP11-241J12.3 targeting pyruvate carboxylase promotes hepatocellular carcinoma aggressiveness by disrupting pyruvate metabolism and the DNA mismatch repair system.

Authors:  Liuliu Cheng; Shichuan Hu; Jinhu Ma; Yongheng Shu; Yanwei Chen; Bin Zhang; Zhongbing Qi; Yunmeng Wang; Yan Zhang; Yuwei Zhang; Ping Cheng
Journal:  Mol Biomed       Date:  2022-02-05

8.  Raising of Anillin expression in para-cancerous hepatocytes is associated with hepatic depolyploidization and short-term recurrence of hepatocellular carcinoma after radical operation.

Authors:  Nan Wang; Fengjie Hao; Yifan Zhang; Wen Xu; Yongjun Chen; Xiaochun Fei; Junqing Wang
Journal:  J Cancer       Date:  2022-05-29       Impact factor: 4.478

9.  Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.

Authors:  Xian Lin; Ai-Min Li; Yong-Hao Li; Rong-Cheng Luo; Yu-Jiao Zou; Yi-Yi Liu; Chen Liu; Ying-Ying Xie; Shi Zuo; Zhan Liu; Zhen Liu; Wei-Yi Fang
Journal:  Signal Transduct Target Ther       Date:  2020-02-14

10.  SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.

Authors:  Jie Li; Ming-Han Li; Tian-Tian Wang; Xiao-Ning Liu; Xiao-Ting Zhu; Yun-Zhang Dai; Ke-Chao Zhai; Yong-da Liu; Jia-Li Lin; Rui-Liang Ge; Shu-Han Sun; Fang Wang; Ji-Hang Yuan
Journal:  Br J Cancer       Date:  2021-07-17       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.